Patents by Inventor Richard Lathe
Richard Lathe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090241207Abstract: A gene trap vector comprises a DNA construct containing an expression unit of an internal ribosome binding site (IRES) coupled to a heterologous gene sequence; this expression unit is used in gene trap protocols to obtain expression of the heterologous gene in the host.Type: ApplicationFiled: February 28, 2006Publication date: September 24, 2009Inventor: Richard Lathe
-
Patent number: 7033779Abstract: The invention concerns a novel method for producing hydroxylated and/or acetylated steroid comprising steps which consist in: culturing yeasts on a medium comprising at least a precursor of such hydroxylated and/or acetylated steroids; then isolating the hydroxylated and/or acetylated steroids from the medium after bioconversion. Said method is characterized in that said yeasts are yeasts transformed so as to express the product of Cyp7b gene. The invention also concerns the modified yeast strains.Type: GrantFiled: October 4, 2000Date of Patent: April 25, 2006Assignee: Transgene S.A.Inventors: Gilles Cauet, Eric Degryse, Pedro Vico, Richard Lathe
-
Publication number: 20050229262Abstract: A method of producing a substance comprising a peptide, involves incorporating a DNA sequence coding for the peptide into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The substance may be an (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The substance will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.Type: ApplicationFiled: May 27, 2005Publication date: October 13, 2005Inventors: Anthony Clark, Richard Lathe
-
Publication number: 20030198986Abstract: This invention provides novel hippocampus-associated proteins and DNA sequences coding therefor. In an investigation of hippocampus-associated proteins by differential screening of a rat hippocampus cDNA library, a cDNA species encoding a novel protein designated Hct-1 was isolated and shown to be a to cytochromes P450. The use of hybridization probes based on the rat Hct-1 sequence has led to the identification of homologues in other mammalian species.Type: ApplicationFiled: February 27, 2003Publication date: October 23, 2003Applicant: BTG International LimitedInventors: Richard Lathe, Kenneth Andrew Rose, Genevieve Stapleton
-
Publication number: 20030145339Abstract: A method of producing a substance comprising a peptide, involves incorporating a DNA sequence coding for the peptide into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The substance may be an (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The substance will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.Type: ApplicationFiled: September 25, 2002Publication date: July 31, 2003Applicant: PPL Therapeutics (Scotland) Ltd.Inventors: Anthony John Clark, Richard Lathe
-
Patent number: 6420353Abstract: Use is provided for a 7&agr;-hydroxy or 7-oxo substituted 3&bgr;-hydroxy-steroid possessing the carbon skeleton of cholesterol, androsterone, pregnenolone or estradiol, or an analogue thereof substituted independently at one or both of the 7- and 3-positions with an ester or ether group, in the manufacture of a pharmaceutical composition for the therapy of neuropsychiatric, immune and/or endocrine disorders or for inducing cognitive enhancement. Uses for Cyp7b enzymes in producing such steroids is also provided together with various novel steroids and test kits and methods for diagnosing the disorders.Type: GrantFiled: October 8, 1998Date of Patent: July 16, 2002Assignee: BTG International LimitedInventors: Richard Lathe, Kenneth Andrew Rose, Jonathan Robert Seckl, Ruth Best, Joyce Lai Wah Yau, Caroline McKenzie Leckie
-
Patent number: 6328956Abstract: Pharmaceutical compositions are disclosed which comprise recombinant viruses containing a DNA fragment encoding a polypeptide recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells. This antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the polypeptide specifically bound by antibody H23.Type: GrantFiled: August 17, 1998Date of Patent: December 11, 2001Assignee: Transgene S.A.Inventors: Pierre Chambon, Marie-Paule Kieny, Richard Lathe, Mara Hareuveni
-
Publication number: 20010042256Abstract: A method of producing a substance comprising a peptide, involves incorporating a DNA sequence coding for the peptide into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The substance may be an (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The substance will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.Type: ApplicationFiled: January 11, 2001Publication date: November 15, 2001Inventors: Anthony John Clark, Richard Lathe
-
Patent number: 6207877Abstract: The invention provides a transgenic mouse which is heterozygous or homozygous for an at least partially defective coagulation factor XIII gene.Type: GrantFiled: September 23, 1999Date of Patent: March 27, 2001Assignee: Aventis Behring GmbHInventors: Gerhard Dickneite, Hubert Metzner, Gerd Zettlmeissl, Ulrich Grundmann, Richard Lathe, Austin Smith, Meng Li
-
Patent number: 6203795Abstract: The application provides a polypeptide and a pharmaceutical composition which comprises said polypeptide, wherein said polypeptide is recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells. This antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the polypeptides specifically bound by antibody H23.Type: GrantFiled: May 22, 1998Date of Patent: March 20, 2001Assignee: Transgene S.A.Inventors: Pierre Chambon, Marie-Paule Kieny, Richard Lathe, Mara Hareuveni
-
Patent number: 6184350Abstract: This invention provides novel hippocampus-associated proteins and DNA sequences coding therefor. In an investigation of hippocampus-associated proteins by differential screening of a rat hippocampus cDNA library, a cDNA species encoding a novel protein designated Hct-1 was isolated and shown to be a to cytochromes P450. The use of hybridization probes based on the rat Hct-1 sequence has led to the identification of homologues in other mammalian species.Type: GrantFiled: March 17, 1999Date of Patent: February 6, 2001Assignee: BTG International LimitedInventors: Richard Lathe, Kenneth Andrew Rose, Genevieve Stapleton
-
Patent number: 6024953Abstract: The present invention relates to a vaccinia virus, characterised in that it contains all or part of a DNA sequence (I) coding for an antigenic glycoprotein of rabies.Type: GrantFiled: April 21, 1994Date of Patent: February 15, 2000Assignee: Transgene S.A.Inventors: Richard Lathe, Marie-Paule Kieny, Robert Drillien, Jean-Pierre Lecocq
-
Patent number: 6007806Abstract: The invention concerns a vector being vaccinia virus, which comprises a heterologous DNA sequence which codes at least for the essential region of a tumor specific protein called T antigen, cloned within a non essential region of the vaccinia virus, as well as regulatory element required for the expression of the DNA sequence in higher cells, the vector is particularly useful as a pharmaceutical composition having a preventive or creative activity against tumors especially tumors caused by a papillomavirus.Type: GrantFiled: December 12, 1997Date of Patent: December 28, 1999Assignee: Transgene S.A.Inventors: Richard Lathe, Marie-Paule Kieny, Guerrino Meneguzzi
-
Patent number: 5976850Abstract: This invention provides novel hippocampus-associated proteins and DNA sequences coding therefor. In an investigation of hippocampus-associated proteins by differential screening of a rat hippocampus cDNA library, a cDNA species encoding a novel protein designated Hct-1 was isolated and shown to be a to cytochromes P450. The use of hybridization probes based on the rat Hct-1 sequence has led to the identification of homologues in other mammalian species.Type: GrantFiled: April 21, 1997Date of Patent: November 2, 1999Assignee: University of EdinburghInventors: Richard Lathe, Kenneth Andrew Rose, Genevieve Stapleton
-
Patent number: 5861381Abstract: A pharmaceutical composition which comprises a recombinant vaccinia virus containing a DNA fragment encoding for a polypeptide recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells is provided. The antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the POLYPEPTIDES specifically bound by antibody H23.Type: GrantFiled: June 7, 1995Date of Patent: January 19, 1999Assignee: Transgene S.A.Inventors: Pierre Chambon, Marie-Paule Kieny, Richard Lathe, Mara Hareuveni
-
Patent number: 5830477Abstract: The present invention relates to a vaccinia virus, characterized in that it contains all or part of a DNA sequence (I) coding for an antigenic glycoprotein of rabies.Type: GrantFiled: June 7, 1995Date of Patent: November 3, 1998Assignee: Transgene S.A.Inventors: Richard Lathe, Marie-Paule Kieny, Robert Drillien, Jean-Pierre Lecocq
-
Patent number: 5744133Abstract: The invention concerns a vector being vaccinia virus, which comprises a heterologous DNA sequence which codes at least for the essential region of a tumor specific protein called T antigen, cloned within a non essential region of the vaccinia virus, as well as regulatory element required for the expression of said DNA sequence in higher cells, the vector is particularly useful as a pharmaceutical composition having a preventive or creative activity against tumors especially tumors caused by a papillomavirus.Type: GrantFiled: December 15, 1994Date of Patent: April 28, 1998Assignee: Transgene S.A.Inventors: Richard Lathe, Marie-Paule Kieny, Guerrino Meneguzzi
-
Patent number: 5476995Abstract: A method of producing a proteinaceous compound, involves incorporating a DNA sequence coding for polypeptide into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The proteinaceous compound may be a (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The proteinaceous compound will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.Type: GrantFiled: August 18, 1992Date of Patent: December 19, 1995Assignee: PPL Therapeutics (Scotland) Ltd.Inventors: Anthony J. Clark, Richard Lathe
-
Patent number: 5366894Abstract: A method of producing a substance comprising a peptide, involves incorporating a DNA sequence coding for the peptide into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The substance may be an (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The substance will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.Type: GrantFiled: November 22, 1991Date of Patent: November 22, 1994Assignee: Pharmaceutical Proteins LimitedInventors: Anthony J. Clark, Richard Lathe
-
Patent number: 5322775Abstract: A method of producing a proteinaceous compound, involves incorporating a DNA sequence coding for a polypeptide chain of said compound into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The proteinaceous compound may be a (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The proteinaceous compound will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.Type: GrantFiled: November 22, 1991Date of Patent: June 21, 1994Assignee: Pharmaceutical Proteins Ltd.Inventors: Anthony J. Clark, Richard Lathe